Danish group says anti-depressant submission to US delayedShares in Danish pharmaceutical group H. Lundbeck plummeted Monday after it said it would be up to two years late in submitting a new anti-depressant to US authorities for approval. The company, which is developing the drug in conjunction with the Japanese firm Takeda, said the delay was due to unconvincing un·con·vinc·ing adj. Not convincing: gave an unconvincing excuse. un initial results from three clinical studies for the new Lu AA21004 drug. The medication is being developed to replace the most widely used antidepressant antidepressant, any of a wide range of drugs used to treat psychic depression. They are given to elevate mood, counter suicidal thoughts, and increase the effectiveness of psychotherapy. , Celexa/ Lexapro Lex·a·pro A trademark for the drug escitalopram oxalate. escitalopram oxalate Cipralex (UK), Lexapro Pharmacologic class: Selective serotonin reuptake inhibitor Therapeutic class: . Lundbeck shares were down more than 13.5 percent on the Copenhagen exchange at mid-morning. Company chief Ulf Wiinberg said Lundebck did not yet have plans for further tests and would discuss the matter with Takeda. The company said in a statement that "Lundbeck and Takeda will continue to work with the US Food and Drug Administration and other regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. on the clinical development program and submission plans." Depression affects 121 million people around the world, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Lundbeck. 
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion